UPL Limited Q1 FY27 Results

UPL's consolidated Q1 FY27 revenue rose 10.5% YoY to ₹10,181 Cr (from ₹9,216 Cr), but the Group still posted a net loss of ₹73 Cr for the period — roughly half the ₹176 Cr loss a year ago. The composition matters: profit attributable to owners of the parent swung positive to ₹10 Cr from an ₹88 Cr loss, while the ₹83 Cr loss now sits with non-controlling interests. Basic EPS was ₹0.12. Sequentially revenue fell 44.5% from ₹18,335 Cr, but that is agrochemical seasonality (the Jan–Mar Rabi quarter is the year's strongest, Apr–Jun the weakest), not a slowdown; QoQ should not be read as the story here.

The swing to a narrower loss is led by deleveraging: finance costs dropped to ₹852 Cr from ₹1,007 Cr YoY (−15%), the clearest evidence the debt-reduction campaign we flagged pre-result is feeding through. Crop protection revenue grew 5.7% to ₹7,659 Cr and Seeds & Post-harvest 24.6% to ₹1,750 Cr; total segment EBIT was ₹1,110 Cr vs ₹985 Cr. One caveat on the loss-narrowing: other income carries a one-off ₹55 Cr Bombay High Court insurance arbitral award — strip it (the year-ago period had no equivalent) and the underlying loss is closer to ₹128 Cr, so the ~58% reported loss-narrowing overstates; the adjusted narrowing is nearer ~27%. Net margin improved (−0.7% vs −1.9% YoY) while operating margin held around 16%.

The stock went into the print at ₹621.45, up 2.3% over the past month of trading.

Against the bar we set in our preview — ₹11,700–12,100 Cr revenue and +14–18% EBITDA — the print missed: revenue landed 13–16% below and EBITDA was broadly flat, so management's own 14–18% EBITDA guidance was not met this quarter, though the 10–14% revenue-growth guide was met at its low end. Street had built the FY27 thesis on ~72% consolidated profit growth; a still-loss-making Q1 is a soft (if seasonally weakest) start. On the corporate front, the Composite Scheme of Arrangement (UPL SAS amalgamation, appointed date April 1, 2026) received BSE/NSE observation letters on July 29 but has no P&L effect yet, pending NCLT and shareholder approvals; the $1 Sustainable Tech acquisition and the Bioplanta stake divestment are immaterial. Standalone, revenue fell 15.8% YoY to ₹1,397 Cr with PAT of ₹89 Cr (vs ₹122 Cr) — the standalone entity is a small slice of the Group, so the consolidated picture governs.

UPL reports on August 3, 2026 amid a landmark corporate restructuring: the Composite Scheme of Arrangement and ESOP swap closed effective July 31 (swaps completed, NSE/BSE observation letters in hand). The street's focus has shifted from balance-sheet repair—accomplished in FY26 with a 4x PBT and 2.5x operational PATMI beat—to margin expansion and growth capital deployment. With FY26 delivery of ₹52,000 Cr revenue (+11% YoY) and ₹1,800 Cr debt reduction locked for H1, Q1 sets the tone for a full year of normalized working capital and top-line acceleration.

A strong Q1: Revenue at the top of guidance (₹12,000+ Cr), EBITDA margin expansion reaching or exceeding 150 bps, and cash generation supporting the ₹1,800 Cr debt paydown on track. Organic growth in key geographies (India, LatAm, EMEA) outpacing the guided 10–14%, with gross margin stable or better despite commodity input cycles. Management maintains FY27 full-year revenue growth at 8.6% and profit growth 72.3%, signaling no demand shocks. A weak Q1: Revenue at the bottom of guidance (₹11,700 Cr, mid-single-digit growth), margin pressure from unamortized overhead costs post-restructuring, or EBITDA growth lagging the 14% lower bound. Any deterioration in receivables or inventory working capital would flag execution risk on the ₹1,800 Cr deleveraging commitment. Guidance cut on FY27 would reset valuations sharply.

Yes, barring external shock. FY26 was a breakout year—the company beat its own guidance across revenue, EBITDA, and PBT, cut debt by ₹1,500 Cr despite a restructuring, and set ₹1,800 Cr deleveraging for H1 FY27. The closing of the Scheme (swap transactions complete by July 31) removes a structural overhang and clears the path for management to pivot from repair to growth. Q1 FY27 is the first print under this new capital regime; Street expects normalcy: mid-teen revenue growth, margin gains from operational leverage, and no surprises on debt reduction. The interim trading window closed June 30 (standard pre-result blackout), so insider positioning is frozen; FII ownership rose 211 bps to 43.10% in Q4 (vs 42.89% in Q3), a sign that large capital found value at lower prices. The 300% final dividend (₹6/share) approved in June telegraphs management confidence in free cash flow.

UPL at ₹604.3 (July 31 close) is 25.6% off ATH ₹812.2, set in mid-2024 before the restructuring overhang and agchem cycle deceleration. Volume trend is normal. RSI at 55.5 (neutral, not oversold). Stock trades below 20-day SMA (₹603) by 1 point, but sits below 50-day (₹611) and 200-day (₹677) moving averages—a downtrend, albeit shallow. FII ownership at 43.10% (+211 bps QoQ) suggests large capital is accumulating into the result, implying confidence in the result and restructuring close.

Revenue growth intact at 10.5% YoY, but net profit collapsed to -₹73 Cr despite management's bullish narrative on PATMI. Pricing and FX masked a 3% volume decline. Macro risks (West Asia, El Niño, farm income stress) justified in Q&A pushback; deleveraging trajectory solid but near-term earnings quality suspect.

Analysts pressed hard on volume recovery (Saurabh Jain × 3 questions) and margin sustainability. Management held pricing narrative but conceded India SAS margin normalization. No major evasions; acknowledged macro caution warranted.

Score 6/10. Clear on numbers and strategy; transparent on macro risks. But major discrepancy on PAT overstates earnings quality. Evasive on specific margin normalization timeline. Hit revenue guidance (10.5% vs 10% implied); EBITDA +15%. But PAT -₹73 Cr contradicts 'positive' claim. Track record credible on EBITDA, suspect on net income.